BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Protic M, Schoepfer A, Yawalkar N, Vavricka S, Seibold F. Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels. Scandinavian Journal of Gastroenterology 2016;51:1482-8. [DOI: 10.1080/00365521.2016.1218541] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Kiyohara H, Sujino T, Teratani T, Miyamoto K, Arai MM, Nomura E, Harada Y, Aoki R, Koda Y, Mikami Y, Mizuno S, Naganuma M, Hisamatsu T, Kanai T. Toll-Like Receptor 7 Agonist-Induced Dermatitis Causes Severe Dextran Sulfate Sodium Colitis by Altering the Gut Microbiome and Immune Cells. Cell Mol Gastroenterol Hepatol 2019;7:135-56. [PMID: 30510995 DOI: 10.1016/j.jcmgh.2018.09.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
2 Courbette O, Aupiais C, Viala J, Hugot JP, Louveau B, Chatenoud L, Bourrat E, Martinez-Vinson C. Infliximab Paradoxical Psoriasis in a Cohort of Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2019;69:189-93. [PMID: 30921262 DOI: 10.1097/MPG.0000000000002349] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
3 Yang M, Liu W, Deng Q, Liang Z, Wang Q. The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist: A systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e27510. [PMID: 34678884 DOI: 10.1097/MD.0000000000027510] [Reference Citation Analysis]
4 Godat S, Fournier N, Safroneeva E, Juillerat P, Nydegger A, Straumann A, Vavricka S, Biedermann L, Greuter T, Fraga M, Abdelrahman K, Hahnloser D, Sauter B, Rogler G, Michetti P, Schoepfer AM; Swiss IBD Cohort Study Group. Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort. Eur J Gastroenterol Hepatol 2018;30:612-20. [PMID: 29384798 DOI: 10.1097/MEG.0000000000001078] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
5 Gawdzik A, Ponikowska M, Jankowska-Konsur A, Woźniak Z, Maj J, Szepietowski JC. Paradoxical Skin Reaction to Certolizumab, an Overlap of Pyoderma Gangrenosum and Psoriasis in a Young Woman Treated for Ankylosing Spondylitis: Case Report with Literature Review. Dermatol Ther (Heidelb) 2020;10:869-79. [PMID: 32447747 DOI: 10.1007/s13555-020-00398-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
6 Buckley LH, Xiao R, Perman MJ, Grossman AB, Weiss PF. Psoriasis Associated With Tumor Necrosis Factor Inhibitors in Children With Inflammatory Diseases. Arthritis Care Res (Hoboken) 2021;73:215-20. [PMID: 31646743 DOI: 10.1002/acr.24100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Pérez-de-lis M, Retamozo S, Flores-chávez A, Kostov B, Perez-alvarez R, Brito-zerón P, Ramos-casals M. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opinion on Drug Safety 2017;16:1255-71. [DOI: 10.1080/14740338.2017.1372421] [Cited by in Crossref: 64] [Cited by in F6Publishing: 48] [Article Influence: 12.8] [Reference Citation Analysis]
8 Groth D, Perez M, Treat JR, Castelo-Soccio L, Nativ S, Weiss PF, Lapidus S, Perman MJ. Tumor necrosis factor-α inhibitor-induced psoriasis in juvenile idiopathic arthritis patients. Pediatr Dermatol 2019;36:613-7. [PMID: 31240749 DOI: 10.1111/pde.13859] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
9 Weizman AV, Sharma R, Afzal NM, Xu W, Walsh S, Stempak JM, Nguyen GC, Croitoru K, Steinhart AH, Silverberg MS. Stricturing and Fistulizing Crohn’s Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2018;63:2430-8. [DOI: 10.1007/s10620-018-5096-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
10 Segaert S, Hermans C. Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents. Am J Clin Dermatol 2017;18:771-87. [PMID: 28597181 DOI: 10.1007/s40257-017-0296-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
11 Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease—A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis 2020;14:351-60. [DOI: 10.1093/ecco-jcc/jjz152] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
12 Villalobos-Sánchez L, Larena-Grijalba C, Alía-Jiménez A, Sifuentes-Giraldo WA. Certolizumab pegol-induced palmoplantar pustulosis: A case report and review of the literature. Reumatol Clin (Engl Ed) 2019;15:e163-5. [PMID: 29370988 DOI: 10.1016/j.reuma.2017.12.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Melo FJ, Magina S. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review. Int J Dermatol 2018;57:1521-32. [DOI: 10.1111/ijd.14072] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]